Vivus Weighs In As a Leader for Diet Pills, Cowen Upgrades and Raises PT

Cowen and Company analyst Simos Simeonidis upgraded Vivus

from market perform to outperform and raised the PT from $13.50 to $19. Simeonidis reported that the risk/ reward associated with Vivus “appears compelling” as management changes and retail availability of Qsymia suggest a “significant upside” from current price levels. The diet pill Qsymia is a market leader supplying 60% of the obesity market. In the note, the analyst rates Arena Pharmaceuticals

as new market perform with a PT of $4.50. Simeonidis also initiated Orexigen Therapeutics

with an outperform rating and PT of $10. Vivus closed at $10.19 on Wednesday.